Last reviewed · How we verify
NCT05856409
Clinical Application of 68Ga-FAPI PET Imaging in Detection of Ovarian Cancer Recurrence
trial testing 68Ga-FAPI in 68Ga-FAPI in 20 participants. Status unknown.
1 April 2024
Quick facts
| Lead sponsor | RenJi Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 10 May 2023 |
| Primary completion | 1 April 2024 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- 68Ga-FAPI — full drug profile →
Conditions studied
- 68Ga-FAPI — all drugs for 68Ga-FAPI →
- Ovarian Cancer — all drugs for Ovarian Cancer →
- Epithelial Ovarian Cancer — all drugs for Epithelial Ovarian Cancer →
- Positron Emission Tomography — all drugs for Positron Emission Tomography →
Sponsor
RenJi Hospital
Who can join
Adults 18 to 80, female only, with 68Ga-FAPI or Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective study to investigate the potential efficacy of 68Ga-FAPI PET/CT for recurrence detection of epithelial ovarian cancer in comparison with 18F-FDG PET/CT.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Cancer-Associated Fibroblasts: Origin, Classification, Tumorigenicity, and Targeting for Cancer Therapy.
Fan C, Zhu W, Chen Y, Zhu W, et al · · 2025 · cited 4× · PMID 41164803 · DOI 10.1002/mco2.70415
Verify or expand the search:
- PubMed search for NCT05856409
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of 68Ga-FAPI
Trials testing the same drug.
- NCT07062523 — Analyse of Inflammatory Activity of Sjögren's Syndrome on 68Ga-FAPI PET-CT · Phase 1, PHASE2 · recruiting
- NCT05803629 — Characterizing Histiocytosis With 68Ga-FAPI PET/CT · NA · unknown
- NCT05686876 — FAPI-PET/CT in Psoriatic Arthritis · EARLY_PHASE1 · unknown
- NCT05543954 — 68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients · EARLY_PHASE1 · recruiting
- NCT05275699 — Analyse of Diagnosis Value of Keloid on 68Ga- FAPI-04 PET-CT · Phase 1, PHASE2 · completed
Other RenJi Hospital trials
Trials by the same sponsor.
- NCT07584733 — Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper · Phase 2 · not yet recruiting
- NCT07537725 — EEG-TMS for Postoperative Delirium After Cardiac Surgery · NA · not yet recruiting
- NCT07527936 — A Study of BEN301 Injection in theTreatment of Autoimmune Diseases · EARLY_PHASE1 · not yet recruiting
- NCT07343076 — Efficacy of Immediate Versus Staged Complete Revascularization in Patients With NSTE-ACS and Multivessel Disease (FUTURE · NA · not yet recruiting
- NCT07449793 — Biochemical Response and Clinical Outcomes in Patients With PBC · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05856409 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by RenJi Hospital
- Last refreshed: 16 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05856409.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing